What Mid Atlantic Bio Angels does

Mid Atlantic Bio Angels is a New York-based angel investment group founded in 2012 that focuses on funding early-stage life science and biotechnology companies. The group operates a community-led model, sourcing deals through industry networks, professional referrals, and co-investor relationships within the biotech investment community. Its core activity centers on syndicated angel rounds, typically with total deal sizes under $30 million, providing both capital and sector-specific due diligence expertise to portfolio companies. The organization serves two primary constituencies: early-stage life science and biotech startups seeking capital and specialized guidance, and angel investors seeking curated exposure to vetted biotech deal flow.

The group's investment approach emphasizes strong management teams, realistic market assessments, clear milestones, and viable exit pathways, with an explicit preference for acquisition exits over IPOs. Mid Atlantic Bio Angels generates returns through carried interest on successful investments and exit proceeds from portfolio companies, rather than through management fees or a technology product offering. The company is led by founder Yaniv Sneor and co-founder Stephen Goodman, whose domain expertise in life science due diligence and commercial alignment is central to the group's positioning as a specialist in a sector where rigorous evaluation is critical. No proprietary technology platform, software product, or AI-driven tooling is disclosed.

The competitive position of Mid Atlantic Bio Angels rests on domain specialization and network effects within the biotech investment community. It addresses the capital gap for early-stage life science companies that struggle to secure traditional venture funding, while providing investors with curated deal flow and rigorous due diligence in a high-risk, specialized sector. The group has maintained continuous operation since founding, with active deal participation as recently as April 2026. There is no disclosed institutional backing, parent company, or external funding; the group operates as an independent angel collective.

Name

Mid Atlantic Bio Angels

Website

https://bioangels.net

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Mid Atlantic Bio Angels is a New York-based angel investment group founded in 2012 that funds early-stage life science and biotechnology companies through syndicated rounds typically under $30 million, providing capital and specialized due diligence expertise to biotech startups and curated deal flow to angel investors.

Ownership category

akta.pro rank

Product category

Angel Investment Services

NAICS

Other Financial Vehicles (525990)

SIC

Investment Advice (6282)

akta.pro primary industry

Micro-VC & Angel Funds (FSANAAAI)

akta.pro secondary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Angel investing
• Life science funding
• Biotech venture capital
• Early-stage investment
• Syndicated funding rounds

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Investment returns and carried interest: As an angel investment group, Mid-Atlantic Bio Angels generates returns through carried interest on successful investments and exit proceeds from portfolio companies. The group participates in syndicated investment rounds with typical deal sizes under $30 million total investment.

Go-to-market motion1 record

Core offering

Mid Atlantic Bio Angels is a life science angel investment group that deploys early-stage capital into new and emerging biotech and life science companies through syndicated investment rounds, typically with total deal sizes under $30 million. The group pairs funding with specialized due diligence expertise, milestone-based investment criteria, and guidance on exit pathways, with a stated preference for acquisition exits over IPOs.

Product overview

Mid Atlantic Bio Angels is a life science angel investment group that provides funding and advisory support to early-stage biotech companies. The organization does not appear to offer a software product, platform, or technology service offering based on available source data. The company focuses on connecting biotech entrepreneurs with angel investors and conducting due diligence on potential investments.

Differentiator

Problem solved

Functional benefit

Products and services

• Early-stage life science angel investment Angel investment funding for early-stage biotech and life science companies, deployed through syndicated rounds typically totaling under $30 million, paired with specialized due diligence, milestone-based investment criteria, and exit pathway guidance with a preference for acquisition exits. Targeted at founders and management teams of early-stage life science and biotech startups.
• Specialized life science due diligence Domain-specific due diligence tailored to evaluating early-stage therapeutic and diagnostic opportunities, providing investors and portfolio companies with rigorous assessment of management teams, market viability, milestones, and exit pathways.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves3 records

Expansion highlights2 records

Direct peers

• Life Science Angels: One of the largest and most active angel investor groups in the U.S. focused exclusively on life-science and biotech deals. Directly comparable to Mid-Atlantic Bio Angels in target sector, due-diligence approach, and syndicated angel structure.
• Band of Angels: Silicon Valley–based angel group with active life-science and healthcare deal flow. Comparable in operating model (syndicated angel investing with domain-focused sub-groups) and in serving as a feeder into larger biotech rounds.
• Keiretsu Forum: Large global angel investor network with chapters across multiple regions including the U.S. East Coast. Comparable in syndicated angel structure and in active life-science deal flow, with a similar member-driven deal-sourcing model.
• Tech Coast Angels: One of the largest U.S. angel networks, with healthcare and biotech investments alongside tech. Comparable as a large syndicated angel platform with formal due-diligence processes and a chapter-based structure.
• Golden Seeds: Angel investment group with a focus on women-led companies, including a meaningful life-science and healthcare portfolio. Comparable in syndicated angel structure, New York presence, and sector-aware due diligence.

Regional players

• New York Angels: Established New York–based angel network investing across sectors including life sciences. Comparable as a regionally anchored angel collective operating in the same geographic market as Mid-Atlantic Bio Angels.
• BioEnterprise: Regional life-science commercialization and investor-relations organization. Comparable as an ecosystem player supporting biotech deal flow in the broader U.S. Northeast/Midwest region.

Broad incumbents

• Angel Capital Association: Industry association for U.S. angel groups. Comparable as a broader ecosystem participant that supports the operating environment Mid-Atlantic Bio Angels operates in, rather than a direct investing peer.

Emerging players

• ARCH Venture Partners: Large biotech-focused venture firm that frequently co-invests with or follows angel-led rounds. Comparable as a sector specialist that overlaps in target deal type (early-stage life sciences) but operates at materially larger check sizes.
• Atlas Venture: Biotech-focused early-stage venture firm that often enters at the seed/Series A stage. Comparable in target stage and sector but with a much larger fund and institutional LP base.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/BioAngelsGroup
• LinkedInlinkedin.com/company/mid-atlantic-bio-angels

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments27 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mid Atlantic Bio Angels